Investigators asked a concrete question: do routine histopathological images of primary early-stage melanoma contain prognostic information not captured by staging? The population-based D-ESMEL study set out to answer this using digital pathology. The authors trained a model to predict later distant metastasis from diagnostic slides, reasoning that tile-level morphologic features might stratify risk even when AJCC stage is identical. The report is a preprint and has not completed peer review; the study team noted that these results should not yet direct clinical care.
The dataset came from a Dutch, population-based source. A discovery set comprised n=328 case-control sets; those were matched on follow-up time and established prognostic covariates including Breslow thickness, ulceration, age, and sex. For validation, the authors constructed a nested case-control (NCC) cohort drawn from a broader registry of more than 5,500 patients; the validation analysis included n=266 stage-matched controls. Ethical approvals were reported from Erasmus MC committees and national registries. The abstract states that clinical data are not publicly available without permission, and that histopathological images and clinical data can be provided upon reasonable request to the authors and with permission from the Netherlands Comprehensive Cancer Organisation.
The study team developed an end-to-end deep learning workflow to select relevant patches automatically from diagnostic whole slide images (WSIs) and to generate patient-level metastatic-risk predictions based on histopathology alone. The discovery set served as the training base and the authors used 10-fold cross-validation during development. The abstract does not specify network architecture, tile size, augmentation strategies, or training hyperparameters; those methodological details were not reported in the abstract and may appear in the full manuscript or supplementary files.
Model performance on cross-validation folds in the discovery set varied; the best validation fold achieved a balanced accuracy of 0.88. The mean balanced accuracy across folds was reported as 0.81 with a 95% confidence interval of 0.77–0.85. In the external validation using the NCC cohort, the histopathology-derived predictions retained prognostic signal and were associated with subsequent metastasis. The abstract reports an adjusted odds ratio of 1.97 with p<0.01 for the model predictions in the validation cohort. The authors also reported discrimination using the weighted C-index: the deep learning predictions alone achieved a C-index of 0.86, while AJCC stage alone had a C-index of 0.80. Combining the model predictions with AJCC stage raised the C-index to 0.87, and this combined metric was significantly higher than stage alone (p<0.001).
The investigators examined whether the histopathology-based predictions added information beyond standard clinical staging. In multivariable analysis the model output remained an independent prognostic factor after adjustment, as reflected by the adjusted OR of 1.97 (p<0.01) reported in the abstract. The improvement in discrimination when adding the model to AJCC stage (C-index increase from 0.80 to 0.87) suggested incremental prognostic value. The abstract does not provide full multivariable model coefficients, calibration plots, or subgroup C-index values; those elements were not reported in the abstract text.
The authors declared no competing interests and listed ethical approvals from Erasmus MC and national pathology and cancer registries. They emphasized that the clinical dataset used is available only with permission from the Netherlands Comprehensive Cancer Organisation and upon reasonable request to the authors. The report is a preprint and consequently has not been certified by peer review. The abstract notes that further investigations of the underlying biological features are needed to translate histopathology-derived signals into clinical decision-making. The abstract did not specify the deep learning architecture, per-patient decision thresholds, nor detailed external replication beyond the NCC validation cohort; readers should consult the full preprint and supplementary material for those technical details and for any additional limitations documented by the authors.